Abstracts Archive - Page 2080 of 2607 - ACR Meeting Abstracts

Abstract Number: 2329 • 2014 ACR/ARHP Annual Meeting
Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. a Descriptive Study Using the STAR-Etic Registry
Elisabet Lindqvist¹, Margreth Grotle², Kim Hoerslev-Petersen³, Theodora P.M. Vliet Vlieland⁴ and Ann B. I. Bremander⁵, ¹Department of Clinical Sciences, Lund, Section for Rheumatology, Lund, Lund University and Skåne University Hospital, Lund, Sweden, ²Rheumatology, National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway, ³Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁴Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands, ⁵Spenshult Research and Development Center, Halmstad, Sweden
Background/Purpose: The frequency of admission to rehabilitation varies among countries but also among diagnosis groups. So far research describing and comparing the rehabilitation in various…
Abstract Number: 2330 • 2014 ACR/ARHP Annual Meeting
Construct Validity of the Adult Myopathy Assessment Tool in Individuals with Inclusion Body Myositis
Michael Harris-Love¹, Galen Joe², Todd Davenport³, Joseph Shrader², Beverly McElroy⁴, Goran Rakocevic⁵, Olavo Vasconcelos⁶ and Marinos Dalakas⁵, ¹Geriatrics Service, VA Medical Ctr, Washington, DC, ²Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, ³Department of Physical Therapy, University of the Pacific, Stockton, CA, ⁴National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, ⁵Department of Neurology, Thomas Jefferson University, Philadelphia, PA, ⁶Department of Neurology, Richmond Veterans Affairs Medical Center, Richmond, VA
Background/Purpose The Adult Myopathy Assessment Tool (AMAT) is a 13-item performance-based battery developed to assess function and anaerobic endurance in adults with muscle disease. The…
Abstract Number: 2331 • 2014 ACR/ARHP Annual Meeting
People’s Views, Beliefs and Experiences of Exercise for Chronic Hip and Knee Pain: Cochrane Review with Qualitative Synthesis
Professor Mike Hurley¹, Kelly Dickson², Hanan Hauari³, Dr Nicola E. Walsh⁴, Robert Grant⁵, Jo Cumming⁶ and Sandy Oliver³, ¹School of Rehabilitation Sciences, St George's University of London and Kingston University, London, United Kingdom, ²Social Science Research Unit, Institute of education University of London, London, United Kingdom, ³Social Science Research Unit, Institute of Education University of London, London, United Kingdom, ⁴Allied Health Professions, University of the West of England, Bristol, United Kingdom, ⁵Faculty of Health, Social Care and Education, St George's University of London and Kingston University, London, United Kingdom, ⁶Information, Arthritis Care, London, United Kingdom
Background/Purpose: Chronic peripheral joint pain is extremely prevalent and a major cause of physical and psychosocial dysfunction. Exercise improves pain and physical function, but the…
Abstract Number: 2332 • 2014 ACR/ARHP Annual Meeting
Use of Wrist Hand Orthoses during Hand Function Skills and Functional Tasks By Adults with and without Rheumatoid Arthritis
Janet L. Poole¹, Kelly Nunez² and Patricia Burtner³, ¹Occupational Therapy Program, University of New Mexico, Albuquerque, NM, ²Occupational Therapy, Veteran's Administration Medical Center, Albuquerque, NM, ³Occupational Therapy, University of New Mexico, Greenbank, WA
Background/Purpose : To determine changes in muscle activation in the upper extremity using electromyography (EMG) when static and dynamic orthoses are worn by adults with and…
Abstract Number: 2292 • 2014 ACR/ARHP Annual Meeting
Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort
Ginger L. Janow¹, Laura Schanberg², Soko Setoguchi³, Elizabeth D. Mellins⁴, Rayfel Schneider⁵, Yukiko Kimura^1,6 and The CARRA Registry Investigators⁷, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁷Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: Systemic JIA (sJIA) is a rare disease whose treatment has changed in the past 10 yrs. The Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
Abstract Number: 2294 • 2014 ACR/ARHP Annual Meeting
The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom
Timothy Beukelman¹, Roberto Carrasco², Yukiko Kimura³, Laura Schanberg⁴, Wendy Thomson⁵, Kimme L. Hyrich⁶, For the CARRA Registry Investigators⁷ and For the CAPS Investigators Group⁸, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁴Duke University, Durham, NC, ⁵Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷CARRA, Durham, NC, ⁸CAPS, Manchester, United Kingdom
Background/Purpose: Systemic JIA (sJIA) treatment has changed dramatically with the introduction of biologic agents, although treatment approaches may differ between countries. We characterized and compared…
Abstract Number: 2295 • 2014 ACR/ARHP Annual Meeting
A Pharmacometric Based Analysis of the Occurrence of Selected Safety Events of Special Interest and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients
Micha Levi¹, Thomas Dumortier², Nicolino Ruperto³, Hermine H. Brunner⁴ and Olivier Luttringer², ¹Novartis Pharmaceutical Corporation, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, PRCSG-Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose Canakinumab (CAN), a human, selective anti-interleukin-1β monoclonal antibody, has demonstrated rapid and sustained efficacy in systemic juvenile idiopathic arthritis (SJIA) patients,1and is approved in…
Abstract Number: 2296 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia
Ekaterina Alexeeva^1,2, Saniya Valieva¹, Rina Denisova¹, Tatyana Bzarova¹, Kseniya Isayeva¹, Tatyana Sleptsova¹, Elena Mitenko¹, Evgeniya Chistyakova^1,2, Anna Fetisova¹ and Olga Lomakina³, ¹Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ³Scientific Center of Children's Health of RAMS, Moscow, Russia
Background/Purpose Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…
Abstract Number: 2297 • 2014 ACR/ARHP Annual Meeting
Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria – an Analysis of 12-Week Pooled Data
A. Ravelli¹, H. I. Brunner², N. Ruperto¹, P. Quartier³, A. Consolaro⁴, N.M. Wulffraat⁵, K. Lheritier⁶, C. Gaillez⁶, A. Martini¹ and D.J. Lovell², ¹PRINTO-Istituto Gaslini, Genova, Italy, ²PRCSG, Cincinnati, OH, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Pediatria II, PRINTO-Istituto Gaslini, Genova, Italy, ⁵UMC Utrecht, Utrecht, Netherlands, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose Chronic active disease and persistent synovial inflammation can lead to structural damage, joint destruction and impairment of physical function in patients with systemic juvenile…
Abstract Number: 2298 • 2014 ACR/ARHP Annual Meeting
Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data
A. Ravelli¹, H.I. Brunner², N. Ruperto¹, P. Quartier³, A. Consolaro¹, N.M. Wulffraat⁴, K. Lheritier⁵, C. Gaillez⁵, A. Martini¹ and D.J. Lovell², ¹Istituto Gaslini-PRINTO, Genova, Italy, ²PRCSG, Cincinnati, OH, ³Necker-Enfant Malades Hospital, Paris, France, ⁴UMC Utrecht, Utrecht, Netherlands, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose Key objectives of biologic therapies in systemic juvenile idiopathic arthritis (SJIA) are to induce and maintain inactive disease, according to the ACR 2011 definition.…
Abstract Number: 2299 • 2014 ACR/ARHP Annual Meeting
M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis
Christine Petri¹, Steffen Thiel², Jens Christian Jensenius² and Troels Herlin¹, ¹Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ²Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose The lectin pathway of the complement plays a crucial role in the pathogenesis of various inflammatory processes. The lectin pathway proteins are activated through…
Abstract Number: 2300 • 2014 ACR/ARHP Annual Meeting
Biologic Treatment in Systemic Juvenile Idiopathic Arthritis: Single Center Experience
Buthaina Al adba¹, Rayfel Schneider² and Earl Silverman³, ¹paediatric rheumatology, sickkids hospital, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada
Background/Purpose: The prevalence of juvenile idiopathic arthritis (JIA) is approximately 3.3/1000 children and 10- 15% have the systemic form (SJIA). Biologics, specifically anti-IL -1 and…
Abstract Number: 2301 • 2014 ACR/ARHP Annual Meeting
The New Proposal Classification Criteria for Juvenile Spondyloarthropaties
Ozgur Kasapcopur¹, Metin Sezen¹, Kenan Barut¹ and Cengizhan Acikel², ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ²Department of Bioistatistics, Gulhane Military Medical Academy, Ankara, Turkey
Background/Purpose Juvenile spondyloarthropathies (JSpA) are a group of rheumatologic diseases with a disease onset before 16 years of age and are characterized with enthesitis, lower…
Abstract Number: 2302 • 2014 ACR/ARHP Annual Meeting
Classification of Juvenile Spondyloarthropathies According to ASAS Criteria
Marìa M. Katsicas¹ and Ricardo A. G. Russo², ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose The juvenile spondyloarthropathies (JSpA) are a group of related seronegative rheumatic diseases characterized by involvement of the axial , peripheral large joints and entheses.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].